CN1695610A - Compsn. of medication of silybum mariamum - Google Patents
Compsn. of medication of silybum mariamum Download PDFInfo
- Publication number
- CN1695610A CN1695610A CN 200510013390 CN200510013390A CN1695610A CN 1695610 A CN1695610 A CN 1695610A CN 200510013390 CN200510013390 CN 200510013390 CN 200510013390 A CN200510013390 A CN 200510013390A CN 1695610 A CN1695610 A CN 1695610A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- micro
- silibinin
- releasing system
- cremophor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A silibinin composition is prepared from silibinin and the self-emulsifying medicine-releasing system composed of the surfactant (polyoxyvinyl castor oil derivative), cosurfactant (ethanol or diethanediol monoether) and oil phase (medium-chain triglyceride glycerate or edible plant oil).
Description
Technical field
The present invention relates to the pharmaceutical composition of silibinin, the prescription of said composition is applicable to the preparation of peroral dosage forms such as soft capsule, liquid capsule.
Background technology
Silibinin (Silybin) is extraction separation and flavanolignan's class monomer component of obtaining from feverfew Herba Silybi mariani (Silybum marianum) fruit; the effect that has protection and stablize liver plasma membrane; and can promote liver cell regeneration, be mainly used in diseases such as the various acute, chronic hepatitis of treatment, the poisoning of first cirrhosis regulating liver-QI.The molecular formula of silibinin: C
25H
22O
10Chemical name is that 2 α-[2,3-is trans-2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-yl]-2,3-dihydro-3 β, 5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone monohydrate, be off-white color or pale yellow powder, almost insoluble in water, soluble,very slightly in ethanol, and in acetone slightly soluble.The dosage form of silibinin preparation mainly contains ordinary tablet and capsule formulation at present.Be limited to silibinin and be insoluble in water and common organic solvents, oral absorption is poor, and its bioavailability is lower, thereby has influenced its clinical efficacy.
In order to improve the bioavailability of silibinin, domestic and international many researcheres have been done a large amount of effort.Seeley guest amine sheet is that the water soluble preparation that organic amine salt is an active component is made in silibinin and the reaction of organic amine meglumine; Silibinin-phospholipid acid choline complex shows stronger fat-soluble, and water solublity reduces, and promotes drug molecule combine with cell membrane and promotes absorption, the raising bioavailability of medicament.
Summary of the invention
The pharmaceutical composition that the purpose of this invention is to provide a kind of new silibinin, silibinin and surfactant, cosurfactant, oil phase be combined into the pharmaceutical composition that comprises the active component silibinin, this compositions is under room temperature and gentle agitation, and spontaneous formation particle diameter is less than the oil-in-water Emulsion of 1 μ m in the water.Preparation applicable to peroral dosage forms such as soft capsule, liquid capsule, oral liquids.The present invention can be distributed in the whole gastrointestinal tract fast, has reduced owing to medicine and gastrointestinal wall direct contacts the stimulation that causes, bioavailability improves greatly.
The self-micro-emulsification medicine-releasing system is the solution of the transparent and homogeneous that formed by oil phase, surfactant and cosurfactant, and under ambient temperature and gentle agitation situation, spontaneous emulsification forms particle diameter less than 1 micron Emulsion.Medicine is present in these tiny oil droplets, is distributed in fast in the whole gastrointestinal tract, has reduced owing to medicine and gastrointestinal wall direct contacts the stimulation that causes.Medicine distributes between oil/water is biphase, and the stripping that relies on the huge surface area of tiny oil droplet to improve poorly water soluble drugs has greatly improved bioavailability of medicament.Studies show that the absorption of poorly water soluble drugs, bioavailability and emulsion droplet size are closely related, emulsion droplet is thin more, and it is good more to absorb, and bioavailability is high more.
Pharmaceutical composition of the present invention comprises the silibinin and the self-micro-emulsification medicine-releasing system of effective dose, and wherein, the self-micro-emulsification medicine-releasing system is made up of surfactant, cosurfactant and oil phase.
Weight ratio=1 of silibinin and self-micro-emulsification medicine-releasing system: 5-100 in the pharmaceutical composition of the present invention.Preferred 1: 15-30.
The surfactant of self-micro-emulsification medicine-releasing system, cosurfactant and oil phase percentage ratio are in the pharmaceutical composition:
Surfactant 20～60%
Cosurfactant 0.1～40%
Oil phase 20～50%
Above-mentioned surfactant is meant that selecting the HLB value for use is 10 to 19 hydrophilic surfactant active, and this class surfactant is a castor oil derivatives: Cremophor EL, Cremophor RH40, Cremophor 60 (being German BASF AG produces); Or Tweens: Tween 80, Tween 65, Tween 20 or wheat pool class (Myrj 52) one of or they optional two or more.Preferential is castor oil derivatives.
Above-mentioned cosurfactant is selected ethanol or diethylene glycol monoethyl ether (trade name: Transcutol P for use, one of France Jia Fasai company produces), or Transcutol P and alcohol mixture, wherein ethanol and Transcutol P ratio are 1: 1-10 is preferably 1: 3-7.
Above-mentioned oil phase is selected midchain glycerine triglyceride (trade name: Labrafac CC, French Jia Fasai company produces) or edible vegetable oil for use, or their mixture; Wherein vegetable oil can be selected Semen Maydis oil, Oleum Ricini, Oleum Glycines, and the best is an Oleum Ricini, and Oleum Ricini and Labrafac CC ratio are preferably 1: 0-10, the best is 1: 0.5-2.
The weight of the pharmaceutical composition of silibinin recited above is formed, and is wherein preferred:
Labrafac?CC 25-40％
Cremophor?RH40 25-50％
Transcutol?P 15-30％
Ethanol 2-6%
Labrafac?CC 12-25％
Oleum Ricini 12-20%
Cremophor?EL 25-50％
Transcutol?P 15-30％
Ethanol 2-6%
Labrafac?CC 12-25％
Oleum Ricini 12-25%
Cremophor?RH40 25-35％
Transcutol?P 15-35％
Oleum Ricini 20-40%
Cremophor?EL 25-45％
Transcutol?P 15-30％
Ethanol 2-6%
When compositions of the present invention is made various dosage form, as required, can add needed adjuvant of concrete dosage form or additives, as antioxidant, flavoring agent, antiseptic or the like, be not subjected to the restriction of listed content.The preparation method of different dosage form can require according to the routine of this dosage form to carry out.
Preparation technology of the present invention adds the cosurfactant sonic oscillation in the silibinin of metering to become solution, and under agitation once more oil phase and surfactant is added in the gained solution, and pack into hard capsules and sealing of mixture makes liquid capsule; Or mixture is pressed into soft capsule with the Zhanang machine.
Pharmaceutical composition of the present invention contains the 35mg silibinin in every capsules, 3 times on the one, each 2, amounted to 6 in one day.
The present composition forms the stable oil-in-water Emulsion of particle diameter less than 1 μ m under room temperature and gentle agitation.The present invention is applicable to the preparation of peroral dosage forms such as soft capsule, liquid capsule.The present invention can be distributed in the whole gastrointestinal tract fast, has reduced owing to medicine and gastrointestinal wall direct contacts the stimulation that causes, bioavailability improves greatly.
The following examples will be made a more detailed description to the present invention.But, should be understood that these embodiment be not be used for limiting of the present invention.
The specific embodiment
The capsular preparation of embodiment 1 silibinin
Preparation technology adds the cosurfactant sonic oscillation in the silibinin of metering to become solution, and under agitation once more oil phase and surfactant is added in the gained solution, and pack into hard capsules and sealing of mixture makes liquid capsule; Or mixture is pressed into soft capsule with the Zhanang machine.Following preparation technology is identical.
Amounts of components (gram)
Silibinin 35
Labrafac?CC 200
Cremophor?RH40 260
Transcutol?P 130
Ethanol 30
Make 1000
Embodiment 2
Amounts of components (gram)
Silibinin 35
Labrafac?CC 100
Oleum Ricini 100
Cremophor?EL 400
Transcutol?P 170
Ethanol 30
Make 1000
Embodiment 3
Amounts of components (gram)
Silibinin 35
Labrafac?CC 130
Oleum Ricini 120
Cremophor?RH40 120
Transcutol?P 200
Make 1000
Embodiment 4
Amounts of components (gram)
Silibinin 35
Oleum Ricini 240
Cremophor?EL 360
Transcutol?P 170
Ethanol 30
Make 1000
Embodiment 5
Amounts of components (gram)
Silibinin 35
Labrafac?CC 130
Oleum Ricini 120
Cremophor?RH40 120
Transcutol?P 170
Ethanol 30
Make 1000
Get amount of embodiment 5 pharmaceutical compositions, add 500ml, in 37 ℃ of water, gentle agitation 5min under the 50r/min rotating speed obtains being with the blue light clear solution, measures at BI-90Plus laser particle analyzer (Nicolet Instrument Co.), the results are shown in Figure 1.Wherein abscissa is represented emulsion particle diameter (1gnm), and vertical coordinate is represented little emulsion droplet number (%), and mean diameter is 57.5nm, and polydispersity (claiming dispersion of distribution index again) is 0.270.
Claims (9)
1, a kind of pharmaceutical composition that contains silibinin is characterized in that it comprises the silibinin and the self-micro-emulsification medicine-releasing system of effective dose, and wherein, the self-micro-emulsification medicine-releasing system is made up of surfactant, cosurfactant and oil phase.
2, pharmaceutical composition according to claim 1 is characterized in that weight ratio=1 of silibinin and self-micro-emulsification medicine-releasing system: 5-100.
Surfactant, cosurfactant and oil phase percentage ratio are in the described self-micro-emulsification medicine-releasing system:
Surfactant 20～60%
Cosurfactant 0.1～40%
Oil phase 20～50%
Surfactant is a castor oil derivatives: Cremophor EL, Cremophor RH40, Cremophor60; Or Tweens: Tween 80, Tween 65, Tween 20 or wheat pool class (Myrj 52) one of or they optional two or more;
Above-mentioned cosurfactant is selected ethanol or diethylene glycol monoethyl ether for use, or diethylene glycol monoethyl ether and alcohol mixture, and wherein ethanol and Transcutol P ratio are 1: 1-10;
Above-mentioned oil phase is selected midchain glycerine triglyceride or edible vegetable oil for use, or their mixture, and wherein vegetable oil can be selected Semen Maydis oil, Oleum Ricini, Oleum Glycines; Oleum Ricini and Labrafac CC ratio are 1: 0-10.
3, pharmaceutical composition according to claim 2, the weight ratio that it is characterized in that described silibinin and self-micro-emulsification medicine-releasing system is 1: 15-30.
4, pharmaceutical composition according to claim 2 is characterized in that described surfactant is a castor oil derivatives.
5, pharmaceutical composition according to claim 2 is characterized in that described oil phase is an Oleum Ricini.
6, pharmaceutical composition according to claim 2 is characterized in that the weight of described self-micro-emulsification medicine-releasing system is formed:
Labrafac?CC 25-40％
Cremophor?RH40 25-50％
Transcutol?P 15-30％
Ethanol 2-6%.
7, pharmaceutical composition according to claim 2 is characterized in that the weight of described self-micro-emulsification medicine-releasing system is formed:
Labrafac?CC 12-25％
Oleum Ricini 12-20%
Cremophor?EL 25-50％
Transcutol?P 15-30％
Ethanol 2-6%.
8, pharmaceutical composition according to claim 2 is characterized in that the weight of described self-micro-emulsification medicine-releasing system is formed:
Labrafac?CC 12-25％
Oleum Ricini 12-25%
Cremophor?RH40 25-35％
Transcutol?P 15-35％。
9, pharmaceutical composition according to claim 2 is characterized in that the weight of described self-micro-emulsification medicine-releasing system is formed:
Oleum Ricini 20-40%
Cremophor?EL 25-45％
Transcutol?P 15-30％
Ethanol 2-6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100133907A CN100335050C (en) | 2005-04-30 | 2005-04-30 | Compsn. of medication of silybum mariamum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100133907A CN100335050C (en) | 2005-04-30 | 2005-04-30 | Compsn. of medication of silybum mariamum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1695610A true CN1695610A (en) | 2005-11-16 |
| CN100335050C CN100335050C (en) | 2007-09-05 |
Family
ID=35348599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100133907A Expired - Fee Related CN100335050C (en) | 2005-04-30 | 2005-04-30 | Compsn. of medication of silybum mariamum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100335050C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342167B (en) * | 2007-07-10 | 2012-03-21 | 陈亚玲 | Medicament composition |
| CN103285401A (en) * | 2013-05-27 | 2013-09-11 | 沈阳药科大学 | Composition capable of improving solubility and bioavailability of insoluble medicament |
| CN104688845A (en) * | 2015-03-25 | 2015-06-10 | 江苏永璋伟业健康科技有限公司 | Method for separating and preparing pyrrole butyric acid self-emulsion from radix ranunculi ternati and application of pyrrole butyric acid self-emulsion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100342942B1 (en) * | 1999-07-05 | 2002-07-02 | 민경윤 | Oral micro-emulsion composition comprising Carduus marianus extract or silybin isolated therefrom |
-
2005
- 2005-04-30 CN CNB2005100133907A patent/CN100335050C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342167B (en) * | 2007-07-10 | 2012-03-21 | 陈亚玲 | Medicament composition |
| CN103285401A (en) * | 2013-05-27 | 2013-09-11 | 沈阳药科大学 | Composition capable of improving solubility and bioavailability of insoluble medicament |
| CN104688845A (en) * | 2015-03-25 | 2015-06-10 | 江苏永璋伟业健康科技有限公司 | Method for separating and preparing pyrrole butyric acid self-emulsion from radix ranunculi ternati and application of pyrrole butyric acid self-emulsion |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100335050C (en) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150889C (en) | Oral Micro-emulsion composition of silybin | |
| CN1169525C (en) | Pharmaceutical formulations for taxanes | |
| CN1250377A (en) | Hydrophilic binary systems for the administration of cyclosporine | |
| CN1283235C (en) | Clear and stable propofol composition | |
| CN1872048A (en) | Drop pills of soybean aglycone, and preparation method | |
| CN1709460A (en) | Dropping pill of folium ilicis hainanensis and its preparing method | |
| CN100335050C (en) | Compsn. of medication of silybum mariamum | |
| CN1823732A (en) | Poly olefinic taxadol self assembled precusor liposome and its preparation method | |
| CN1215839C (en) | Nano granules of solid lipid of tanshinone and its preparation method | |
| CN107281163B (en) | Application of carboxyl compound in aspect of promoting oral absorption of drug-loaded nanoparticle microspheres | |
| CN1638745A (en) | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment | |
| CN1478465A (en) | Biphenyl diester liquid medicinal composition containing fat | |
| CN1615866A (en) | Anti-cold medicine soft capsule and its preparing method | |
| CN1457776A (en) | Self emulsified soft capsule of ginkgo leaf extract and its preparing method | |
| CN1593449A (en) | self emulsifying soft capsule of breviscapine and its preparation | |
| CN1698642A (en) | Baicalin soft capsule and preparation method thereof | |
| CN1535972A (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| CN1309379C (en) | Asari dripping pills and its preparation process | |
| CN100341511C (en) | Itraconazole dripping pill and its prepn | |
| CN1706403A (en) | Self microemulsion of total dragon's blood flavone | |
| CN1732956A (en) | Pharmaceutical soft capsule containing finasteride | |
| CN1686385A (en) | Compound musk drip pill and its preparation method | |
| CN1294902C (en) | Cough and asthma relieving drop pills prepared using dahurian rhododendron leaf | |
| CN1679669A (en) | Polygala dropping balls and preparation thereof | |
| CN1823863A (en) | Panacea grass soft capsule and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tianjin Pacific Pharmaceutical Co., Ltd. Assignor: Tianjin Pacific Pharmaceutical Co., Ltd. Contract record no.: 2012120000011 Denomination of invention: Compsn. of medication of silybum mariamum Granted publication date: 20070905 License type: Exclusive License Open date: 20051116 Record date: 20120312 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070905 Termination date: 20130430 |